Skip to main content
DLHC $4.66 -1.58%
DLHC logo

DLHC · DLH Holdings Corp.

Track DLHC — free
$4.66 -0.08 (-1.58%) At close · Aug 14
Market Cap
$67.54M
Shares
14.49M
All earnings calls

Earnings call · FY2026 Q2

DLH Holdings Corp. Q2 FY2026 Earnings Call

DLH Holdings Corp. Q2 FY2026 Earnings Call

Concluded May 7, 2026 Audio replay
May 7, 2026 28:35 32 turns
Period
FY2026 Q2
Runtime
28:35
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

DLH reported Q2 FY2026 revenue of $59.3 million, down 33.5% year-over-year largely due to small-business set-aside program transitions, while delivering 9.0% adjusted EBITDA margin, $3.8 million in free cash flow, and a new two-year sole-source NIH contract extension.

Federal health and public health missions 15 Procurement timeline and award decisions 10 Small business set-aside erosion 9 Defense and intelligence opportunities 8 Digital transformation and AI 8 Federal funding environment and budget cycle 6

Management tone

Positive

Net tone +35 · low hedging

Grounding quotes
  • “We believe that the current federal funding environment is favorable to DLH.”
  • “We are encouraged by the increase in bidding activities and are experiencing a busy second half of the fiscal year responding to procurement requests.”
  • “While revenue was down year over year, largely due to the previously discussed program transitions to small business set-aside contracts, these include the VA CMOP and Head Start, we remain committed to maximizing shareholder value.”
  • “What we thought was going to be a pretty quick V-curve turned out to become a little more bathtub, but we are starting to see the opportunities hit now and certainly feel that we'll be able to compete favorably for our share.”

Forward guidance

1 guided metrics

Management's latest ranges and targets are included below.

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue $59.27M -33.6% YoY
Diluted EPS -$0.17 -383.3% YoY
Net income -$2.54M -388.7% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Adjusted EBITDA margin of 9.0% sustained despite revenue decline through cost scaling initiatives
  • Free cash flow of $3.8 million with cash generation expected to accelerate in the second half of fiscal 2026
  • Debt reduced to $132.7 million from $136.6 million, with greater reductions expected before fiscal year-end
  • Awarded a two-year sole-source extension of NIH clinical research support services contract
  • Improved federal funding environment with FY2026 increases for key health agencies and significant defense/intelligence budget increases
  • President's FY2027 budget request calls for historic spending increases in defense and intelligence sector

Risks & pressure points

  • Revenue declined 33.5% year-over-year to $59.3 million, with CMOP and Head Start set-aside transitions driving approximately $24 million of the Q2 impact
  • Net loss of $2.5 million versus net income of $0.9 million in the prior-year period
  • Diluted loss per share of $(0.17) compared to $0.06 earnings per share in prior-year quarter
  • Backlog declined 14.0% to $442.4 million from $514.3 million
  • Adjusted EBITDA declined 43.6% to $5.3 million from $9.4 million year-over-year
  • President's FY2027 budget proposes unspecified reductions in federal health spending, a key DLH market

Key moments

Jump directly to management's words in the synchronized transcript.

“Key federal health agencies received FY 2026 funding increases compared to FY 2025 levels, reversing in part the previously proposed funding reductions outlined by the President's request for fiscal 2026. Agencies in the defense and intelligence market have received significant budget increases that align particularly well with our capabilities.” Zachary C. Parker, CEO
“We expect to convert approximately 50% to 55% of EBITDA generated during fiscal 2026 to reduce debt by year end. We remain well ahead of our mandatory repayment schedule and in full compliance with all financial covenants.” Kathryn JohnBull, CFO

Guidance from the call

Stated verbally and extracted from the transcript.

Metric Guided
Conversion of EBITDA to debt reduction
fiscal 2026
50% – 55%
Full-screen source Call document